BMY Q2 2023 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q2 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.2B-5.6% YoY

Gross Profit

$6.1B54.6% margin

Operating Income

$1.9B17.3% margin

Net Income

$2.1B18.5% margin

EPS (Diluted)

$0.99

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$1.9B

Free Cash Flow

$1.6B

Stock-Based Comp.

$137M

Balance Sheet

Total Assets

$93.5B

Total Liabilities

$61.5B

Stockholders' Equity

$32.0B

Cash & Equivalents

$8.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.2B	$11.9B	-5.6%
Gross Profit	$6.1B	$6.8B	-9.8%
Operating Income	$1.9B	$2.7B	-27.7%
Net Income	$2.1B	$1.4B	+45.9%

Revenue Segments

Eliquis

$3.2B29%

Opdivo

$2.1B19%

Revlimid

$1.5B13%

Orencia

$927M8%

Pomalyst/Imnovid

$847M8%

Yervoy

$585M5%

Mature Products And All Other

$472M4%

Sprycel

$458M4%

Abraxane

$258M2%

Reblozyl

$234M2%

Opdualag

$154M1%

Abecma

$132M1%

Zeposia

$100M1%

Breyanzi

$100M1%

Camzyos

$46M0%

Sotyktu

$25M0%

Geographic Segments

UNITED STATES

$7.9B70%

Rest Of World

$3.2B28%

Other Region

$175M2%